Albatroz Therapeutics Wins the First Amgen Golden Ticket in Singapore

Apr 2023

Leading global biotechnology company Amgen and NSG BioLabs, Singapore’s largest and leading provider of biotech co-working laboratories and offices, recently announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket. Albatroz Therapeutics will be rewarded a one-year free residency in NSG Biolabs’ fully-equipped, turnkey, and certified BSL-2 laboratory, as well as additional facility benefits and connections to Amgen’s scientific and business leaders.

The Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders at a virtual pitch event. In the final round of the competition, 5 finalists pitched their business plans before Amgen’s internal scientific committee that evaluated the strength and novelty of the participants’ scientific rationale, subject matter expertise and business plan viability. In addition to accessing NSG BioLabs’ capabilities, the award winner’s access to a vast network of scientific and business leaders is a key proponent of the Golden Ticket prize – which Albatroz Therapeutics can now leverage to execute its scientific goals.

Launched in early 2022, the Golden Ticket sponsorship was the first sponsorship announced by the NSG Tomorrow Program to accelerate the growth of innovative biotech startups and aid them in executing their vision. NSG Tomorrow seeks to provide crucial support, network access, and environment to empower ambitious biotech startups. With two more Amgen Golden Tickets being up for grabs over the next two years, Amgen and NSG BioLabs stand by their commitment to achieving a shared vision of helping biotech startups grow and facilitating Southeast Asia’s transition into a regional biotech powerhouse.

Launched in 2019, NSG BioLabs has helped its resident startups achieve notable breakthroughs, achieving over SGD 100 million (USD 75 million) in funds raised, major partnerships, and new product launches since 2020.

Albatroz Therapeutics now joins over 20 local and international resident companies with diverse expertise in transformative and life-changing technologies and applications ranging from genome editing to cancer immunotherapy, artificial intelligence, neurodegeneration drug discovery, precision medicine, synthetic biology and more.

(Source: Amgen)

About Us

Orissa International helps companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 companies that includes distributors, resellers, system integrators and local manufacturers, that we have built through advising and guiding more than 5,000 companies with their market expansion into the ASEAN region over the last 25 years.

Orissa International is headquartered in Singapore, with additional offices in Malaysia, Indonesia, Thailand, Vietnam, and the Philippines.

Our Services